In osteoporosis, low cost testing means more widespread testing. More osteoporosis is discovered, and more drugs prescribed for treatment. Norland seeks to capitalize on the opportunity in low-cost testing.
by Roger Longman
By the summer of 1993, Norland Medical Systems BV was nearly bankrupt. The Dutch company had been formed to merge...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
